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a b s t r a c t
Three-dimensional (3D) scaffolds hold great potential for stem cell-based therapies. Indeed, recent
results have shown that biomimetic scaffolds may enhance cell survival and promote an increase in
the concentration of therapeutic cells at the injury site. The aim of this work was to engineer an original
polymeric scaffold based on the respective beneficial effects of alginate and chitosan. Formulations were
made from various alginate/chitosan ratios to form opposite-charge polyelectrolyte complexes (PECs).
After freeze-drying, the resultant matrices presented a highly interconnected porous microstructure
and mechanical properties suitable for cell culture. In vitro evaluation demonstrated their compatibility
with mesenchymal stell cell (MSC) proliferation and their ability to maintain paracrine activity. Finally,
the in vivo performance of seeded 3D PEC scaffolds with a polymeric ratio of 40/60 was evaluated after
an acute myocardial infarction provoked in a rat model. Evaluation of cardiac function showed a signif-
icant increase in the ejection fraction, improved neovascularization, attenuated fibrosis as well as less left
ventricular dilatation as compared to an animal control group. These results provide evidence that 3D
PEC scaffolds prepared from alginate and chitosan offer an efficient environment for 3D culturing of MSCs
and represent an innovative solution for tissue engineering.
1. Introduction
Regeneration of the myocardium is a slow process, limiting car-
diac repair after ischemic injury. Therefore, myocardial infarction
(MI) frequently leads to progressive cardiac damage and, finally,
to heart failure [1]. Previous studies have shown that administra-
tion of autologous bone marrow mesenchymal stem cells (MSCs)
prevents cardiac damage and improves ventricular function after
ischemic insult [2,3]. Most of the beneficial effects of MSCs have
been related to the secretion of a variety of paracrine factors [4–
8]. Therefore, the possibility of concentrating MSCs within or in
proximity of the damaged tissue is an obvious strategy to enhance
the local concentration of secreted paracrine factors. However,
most of the cells injected into the cardiac parenchyma (85%)
die within 3 days of administration [9–14]. This early cell death
significantly decreases the efficacy of cell therapy. An alternative
strategy to intraparenchymal cell injection is the use of tailored
scaffolds providing a biomimetic and protective environment for
MSCs [15,16]. This could improve MSC survival and, consequently,
the enhance the beneficial effects related to the secretion of para-
crine factors.
Alginates are widely used in regenerative medicine because of
their gelling properties under conditions compatible with biologi-
cal activities (37 °C, pH 7.4), their low toxicity after purification
and their high biocompatibility related to their biomimetic struc-
ture. They are a family of naturally derived polymers extracted
frommarine brown algae. Alginates are unbranched binary copoly-
mers consisting of 1,4-linked b-D-mannuronic (M) and a-L-gulu-
ronic (G) residues organized in regions of sequential G units (G-
blocks), regions of sequential M units (M-blocks) and regions of
atactically organized G and M units. The sol–gel transition proper-
ties of alginates are based on the formation of a stiff ‘‘egg-box’’
structure due to the selective binding of divalent cations to
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G-blocks of two adjacent polymeric chains [17]. Alginate associa-
tions with cardiac precursors for myocardium substitute formation
have been proven to have beneficial impact on supporting cell sur-
vival and proliferation [18,19], inducing neovascularization, and
promoting the integration of the structure in a cardiac neoforma-
tion context [20–22]. However, the efficacy of alginate-based
materials is limited by their physical properties [23], and these
materials need to be improved to control the macroporosity in
the resulting scaffolds and to enhance mechanical performance.
In addition, with the goal to take advantage exclusively of the par-
acrine activity of implanted cells, the adhesion properties of algi-
nate scaffolds should be emphasized to optimize cellretention
and promote cell proliferation [15]. Strategies to improve alginate
properties may entail chemical modifications leading to the gener-
ation of potentially toxic reactive intermediates. One alternative to
chemical modifications is to combine alginate with a cationic bio-
compatible polymer to obtain polyelectolyte complexes with im-
proved characteristics.
Chitosan is a cationic copolymer of b(1-4)-2-acetamido-2-
deoxy-b-D-gucopyranose and 2-amino-2-deoxy-b-D-glucopyra-
nose, obtained by deacetylation of naturally occurring chitin. It is
biocompatible and biodegradable, and is able to promote wound
healing [24] and cell adhesion alone [25], or associated with other
polymers [26]. Although its ability to form porous polyelectrolyte
complexes (PECs) when associated with alginates has already been
described [27], the use of alginate- and chitosan-based scaffolds
incorporating MSCs for the treatment of heart failure has never
been proposed.
In the present study, we designed three-dimensional (3D) PEC
scaffolds, and evaluated their physical and biological characteris-
tics and their impact on MSC retention, survival and function. In
addition, we studied the effects of MSCs seeded on 3D PEC scaffolds
in a rat model of acute MI.
2. Materials and methods
2.1. Design of 3D PEC scaffolds and 2D PEC film-coated wells 3D PEC
scaffolds were prepared under aseptic conditions
Alginate (medium-viscosity alginate, Sigma) dispersion: solu-
tions of 1.5% (w/w) alginate were prepared in iso-osmotic saline
solution for 30–120 min at 1200 rpm (Heidolph RZR-2041,
Germany).
Chitosan dispersion: solutions of chitosan (medium MW, Sig-
ma) were prepared in 0.25 M acid acetic iso-osmotic solution
(150 mM NaCl) for 30 min at 1800–2000 rpm (Heidolph RZR-
2041, Germany).
Alginate and chitosan solutions were mixed to obtain polyelec-
trolyte systems containing different weight ratios of alginate to
chitosan (single polysaccharide, and alginate/chitosan weight ra-
tios of 60/40, 50/50 and 40/60).
3D PEC scaffolds, 5 mm diameter  2.5 mm thick, were gener-
ated by a freeze-drying technique described by Shapiro and Cohen
[28]. Briefly, aliquots (100 ll) of polyelectrolyte solutions were
placed in a 96-well plate, frozen overnight at ÿ20 °C and lyophi-
lized. Constructs were cross-linked in an iso-osmotic buffer con-
taining calcium ions (150 mM NaCl, CaCl2, 0.1 M, 12.5 mM Hepes,
pH 7.4) during 60 min. Pure chitosan scaffolds (with a alginate/
chitosan ratio of 0/100) were gellified with 1 M NaOH. Scaffolds
were washed twice (10 min in Hepes buffer) and lyophilized again.
2D PEC films coating the wells of an 8-well microscope slide
were obtained by adding 0.07 g of polyelectrolyte solution to each
well. 2D PEC films were dried overnight at 37 °C and cross-linked
with an iso-osmotic buffer containing calcium ions (150 mM NaCl,
CaCl2, 0.1 M, 12.5 mM Hepes, pH 7.4) for 60 min. Pure chitosan 2D
films were gellified with 1 M NaOH. 2D films were washed twice
(10 min in Hepes buffer, pH 7.4) and dried again at 37 °C.
3D PEC scaffolds and 2D PEC film-coated wells scaffolds were
sterilized by exposure to UV light.
2.2. Scanning electron microscopy (SEM)
SEM analysis of the surface and cross-section of dried 3D PEC
scaffolds was performed with a Leo 435 VP scanning electron
microscope. The scaffold samples were mounted on an aluminum
sample mount and sputter-coated with silver. The specimens were
observed at a 10 kV accelerating voltage. Pore diameter was deter-
mined by measuring the diameter of 10 pores on surface and cross-
section images (n = 10).
2.3. Mechanical properties
The differential elastic moduli and the mechanical behavior of
the scaffolds were measured by three successive uniaxial compres-
sive assays (TA-XT2 texture analyzer, Stable Microsystems, UK).
The apparatus consisted of a mobile probe (314.16 mm2) moving
vertically up and down at a constant and predefined velocity
(0.5 mm sÿ1). The force exerted by the probe on the scaffolds was
recorded as a function of the displacement. The force was con-
verted to stress by reporting the force to the surface of force appli-
cation, and displacement was converted to a strain percentage in
comparison with the initial shape. Differential elastic moduli were
calculated from the stress–strain curves at 50% of strain and repre-
sent the relative stiffness of the scaffold at 50% strain. The differen-
tial elastic modulus was expressed as follows from at least three
independent observations: E50% = [(F50%/S)/Strain]  1000 kPa,
where F50% is the force registered at 50% strain (N) and S is the sur-
face of the specimen (mm2).
2.4. Isolation and culture of human MSCs for in vitro experiments
Human MSCs were isolated from PBS-washed filters used dur-
ing bone marrow (BM) graft processing for allogenic BM transplan-
tation. Cells were cultured at a density of 5  104 cells cmÿ2 in a-
Minimum Essential Medium (a-MEM, Invitrogen, San Diego, CA,
USA) supplemented with 10% fetal calf serum (Hyclone, Logan,
UT, USA) and ciprofloxacin (10 mg mlÿ1; Bayer Schering Pharma,
Germany). After 72 h at 37 °C in 5%CO2, non-adherent cells were
removed and the medium was changed. Cultures were fed every
3–4 days. MSCs were able to differentiate into osteoblasts, chon-
droblasts and adipocytes and were CD90+ (99.1 ± 1.2%), CD45ÿ
(3.6 ± 1.8%), CD34ÿ (1.9 ± 2.3%), CD73+ (100 ± 0%), CD31ÿ
(1.2 ± 0.8%), CD105+ (99 ± 0.7%), CD29+ (99.9 ± 0.05%) and CD13+
(99.9 ± 0.2%), data not shown. MSCs were used between the third
and sixth passages.
2.5. Isolation and culture of rat MSCs for in vivo experiments
MSCs were obtained from BM of Lewis male rats (Harlan,
France) weighing 180–200 g. Anesthesia was performed by intra-
peritoneal injection of pentobarbital (0.1 ml/100 g). BM was
flushed from rat femur with a-MEM (Gibco, France) supplemented
with 10% fetal bovine serum and 1% penicillin/streptomycin (Invit-
rogen, France) and centrifuged (400g, 5 min). Then, cells were pla-
ted in culture flasks (100,000 cells cmÿ2). After 3 days, non-
adherent cells were removed by changing medium, and MSCs were
recovered by their capacity to adhere to plastic culture dishes.
MSCs were then routinely labeled and cultured for the
experiments.
2.6. MSC seeding and cultivation
For in vitro studies, the cells were seeded onto the scaffolds by
dropping 10 ll of cell suspension containing 20,000 cells on top of
the dried scaffolds. After a short centrifugation (400g, 1 min),
seeded scaffolds were hydrated by adjusting the volume of culture
medium. Constructs were cultured at 37 °C in 5%CO2. The medium
was changed every 3–4 days.
2.7. Adhesion measurement with human MSCs
2.7.1. Immunocytochemistry of cytoskeleton proteins
3D PEC scaffolds seeded with hMSCs were fixed with parafor-
maldehyde and incubated with Alexafluor 488-phalloidin (1 h,
1:40, Invitrogen) and mouse anti-human vinculin (1 h, 1:100, Sig-
ma–Aldrich) for detection of actin and focal adhesion, respectively.
Antibody detection was performed by using an Alexafluor 568 sec-
ondary antibody (1:200, 30 min; Invitrogen, CA). For nucleus
detection, sections were incubated with DAPI (0.08 lg mlÿ1,
20 min; Invitrogen, CA).
2.7.2. Confocal imaging
MSCs were cultured on 3D PEC scaffolds for 3 days. After immu-
nostaining of cytoskeleton proteins, 3D PEC scaffolds were photo-
graphed using an Axio Observer Z1 microscope (Zeiss, Germany)
with a 63 objective.
2.7.3. Evaluation of cell spreading
MSCs were cultured on 2D PEC films for 3 days. After immuno-
staining of cytoskeleton proteins, films were analyzed using an
Axio Observer Z1 microscope with a 10 objective. Mean cell area
was determined on randomly selected images (6–7) of 2D PEC
films for each alginate/chitosan proportion (n = 50 cells for each
group).
2.8. Quantification of MSC metabolism activity
Cell metabolism activity was quantified by alamarBlueÒ assay
(Molecular Probes, Invitrogen, France). 3D PEC scaffolds were
transferred to new wells and incubated with 1 ml of minimal
essential medium (Gibco, France) supplemented with 10% of ala-
marBlueÒ reagent for 1–4 h as specified by the manufacturer. Ali-
quots of 100 ll were transferred to a 96-well plate and the
fluorescence was measured at an excitation wavelength of
540 nm and an emission wavelength of 620 nm using a plate read-
er (InfiniteÒ200Pro, Tecan Group).
2.9. Growth factor release
After cell seeding, 3D PEC scaffolds were hydrated by adjusting
the volume of culture medium and cultured at 37 °C in 5% CO2 for
24 h under sterile conditions. The amount of HGF, FGF-2 and VEGF
released into the medium was quantified in the supernatant by
xMAP technologies (Luminex 100™ system, Luminexcorp) with
anti-human HGF, FGF-2 and VEGF antibodies (Ozyme, France).
2.10. In vivo implantation of polyelectrolyte scaffolds
Animals were handled in accordance with the European Animal
Care Guidelines. 3D PEC scaffolds were implanted in adult female
rats (200–250 g) by left thoracotomy via the fourth intercostal
space under general anaesthesia (isoflurane, 2.5%) and mechanical
ventilation. After a pericardectomy, left anterior descending (LAD)
artery was definitively ligated using a 7–0 prolene suture. 3D PEC
scaffolds (alginate/chitosan weight ratio of 40/60) with (5  105
cells, n = 6) or without (n = 4) rat MSCs were implanted just after
MI. Scaffolds were placed on the surface of the left ventricle and
fixed by one suture using a 7-0 prolene suture. The control group
was subjected to the same surgical procedure without scaffold
implantation (n = 3) and sham-operated animals were subjected
to the same surgical procedure without LAD artery ligation and
scaffold implantation (n = 4).
2.11. Blood analysis
Hematocrit measurement was performed on blood collected by
retro-orbital bleeding on anesthetized animals using heparinized
tubes. Hematocrits were evaluated by a standard microhematocrit
method. Leukocyte differential count was performed on total blood
collected from the abdominal aorta (MICROS-60, ABX-Diagnostics,
France).
2.12. Echography
Left ventricular (LV) function was assessed in anesthetized ani-
mals with two-dimensional echocardiography with a General Elec-
tric Vivid 7Ò (GE Medical System, USA) equipped with a 13 MHz
linear probe. Anesthesia was induced with isoflurane and the rats
received continuous inhaled anesthetic (2%) for the duration of
the imaging session. The animals were placed in the supine or lat-
eral position on a warming pad. Numeric images of the heart were
obtained in both parasternal long-axis and short-axis views. 2D
end-diastolic and end-systolic long-axis views of the LV were stan-
dardized as follows: inclusion of the apex, the posterior papillary
muscle, the mitral valve and the aortic root. 2D echocardiographic
measurements were performed with the cine-loop feature to retro-
spectively catch true end-diastolic and end-systolic phases, defined
as the phases in which the largest and the smallest LV cavity size
was obtained, respectively. End-diastolic and end-systolic areas
(A) were obtained by hand tracings of the LV endocardial contours,
according to the American Society of Echocardiography leading-
edge method. On these frames, end-diastolic and end-systolic
lengths (L) of the LV were obtained by tracing a line connecting
the more distal part of the apex and the center of a line connecting
the mitral annular hinge points. End-diastolic and end-systolic vol-
umes (LVEDVs and LVESVs, respectively) were then calculated by
means of the single-plane area–length method (volume = 8  A2/
3  p  L). LV ejection fraction (LVEF,%) was calculated as [(LVEDV
– LVESV)/LVEDV]  100. All measurements were averaged over
three consecutive cardiac cycles and analyzed by a single observer
who was blinded to the treatment status of the animals.
2.13. Histological examinations
Heart tissue specimens were fixed in Carnoy’s solution and
embedded in paraffin.
For light microscopic investigations, paraffin sections (4 lm)
were stained with Sirius red (Sigma Aldrich, France). Three differ-
ent histological preparations obtained from each animal were
scanned (NanoZoomer Digital Pathology) and semiquantified
microscopically using MorphoExpert software. The percentage of
fibrosis was estimated from the Sirius red-stained surface com-
pared to the total heart tissue area without PEC scaffold. Scar
and septum thickness were measured at three different random
sites and relative scar thickness was calculated as the mean scar
thickness/septum thickness.
For immunofluorescence experiments, paraffin sections (4 lm)
were rehydrated and incubated with mouse monoclonal anti-a-
SMA (1:1000, clone 1A4, Sigma, USA) for 2 h. Antibody revelation
was performed by using an Alexafluor 568 secondary antibody
(1:2000, 45 min; Invitrogen, CA). For nucleus detection, sections
were incubated with DAPI (0.08 lg mlÿ1, 20 min; Invitrogen, CA).
The slides were photographed using an Axio Observer.Z1 micro-
scope with a 10 objective. Blood vessel density (number mmÿ2)
was determined by combining counting of a-SMA-positive struc-
tures and morphological analysis. Four randomly selected images
of the ischemic area and border zone stained by a-SMA fluorescent
antibody were quantified for each animal.
2.14. Statistical analysis
Results are expressed as mean ± SEM. Statistical comparison of
the data was performed using the t-test for comparison between
two groups or one-way ANOVA and post hoc Bonferroni’s test for
comparison of more than two groups. A value of P < 0.05 was con-
sidered significant.
3. Results
3.1. Characterization of 3D PEC scaffold complexes
3.1.1. Morphology and porosity of polymeric scaffolds
Three different scaffolds with a constant alginate concentration
(1.5% w/w) and containing 60/40, 50/50 and 40/60 alginate/
chitosan ratios (w/w) were synthesized as described in the Materi-
als and methods section. Control scaffolds composed of pure algi-
nate (1.5% w/w, defined as 100/0 alginate/chitosan ratio) or with
pure chitosan (1.5% w/w, defined as 0/100 alginate/chitosan ratio)
were synthesized according to the same procedure. Fig. 1 shows
SEM images of the surface (Fig. 1A–E) and the cross-section
(Fig. 1F–J) of 100/0 (Fig. 1A and F), 60/40 (Fig. 1B and G), 50/50
(Fig. 1C and H), 40/60 (Fig. 1D and I) and 0/100 (Fig. 1E and J) of
the 3D PEC scaffolds.
All 3D PEC scaffolds displayed an interconnected porosity in
their surface and cross-section. On the surface, the pore density ap-
peared to increase with increasing chitosan proportion. In the
cross-section, scaffolds composed of combined alginate and chito-
san polymers displayed approximately the same pore density as
pure alginate scaffolds. In comparison, pure chitosan scaffolds
exhibited a higher pore density.
Quantitative determination of pore size showed that the mean
pore diameter of the scaffolds was between 50 and 200 lm on
the surface (Fig. 1K) and between 100 and 200 lm in the cross-sec-
tion (Fig. 1L). In particular, the largest pore diameters were ob-
served when scaffolds were synthesized from 60/40 (surface
174 ± 19 lm; cross-section 190.7 ± 20.7 lm) and 40/60 (surface
143.4 ± 14.4 lm; cross-section 200.7 ± 22.8 lm) mixtures.
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Fig. 1. Morphology and porosity of 3D PEC scaffolds with various weight alginate/chitosan weight ratios. Different PEC scaffold formulations were synthesized with various
alginate/chitosan ratios. Scaffold compositions are: 100/0: 1.5% alginate; 60/40: 1.5% alginate + 1% chitosan; 50/50: 1.5% alginate + 1.5% chitosan; 60/40: 1.5% alginate + 2.25%
chitosan; 0/100: 1.5% chitosan. Representative SEM images of scaffold surfaces (A–E) and cross-section (F–J) of 3D PEC scaffolds. Scale bar corresponds to 200 lm.
Determination of surface (K) and cross-section (L) porosity of 3D PEC scaffolds with various alginate/chitosan weight ratios (100/0, 60/40, 50/50, 40/60, 0/100). Measurements
were obtained from SEM images. ⁄P 6 0.05, ⁄⁄P 6 0.01, ⁄⁄⁄P 6 0.001 and based on ANOVA analysis.
3.1.2. Mechanical properties of 3D PEC scaffolds
In order to evaluate the plasticity/viscosity of scaffolds, which is
significant to their in vivo interaction with contractile myocar-
dium, the mechanical behavior of 3D PEC scaffolds was assessed
by compressive tests after rehydratation in a-MEM culture med-
ium. Stress–strain curves recorded during the compression were
not linear for all formulations (Fig. 2A), indicating a non-Hookean
behavior of these polymeric scaffolds. The differential elastic mod-
ulus at 50% strain was determined after three successive compres-
sions with an interval of 30 min to determine if the mechanical
behavior changed in a time-dependent manner (Fig. 2 B). 3D PEC
scaffolds presented higher differential elastic moduli (60/40:
17.1 ± 1.6 kPa; 50/50: 34.5 ± 5.4 kPa; 40/60: 31.0 ± 1.4 kPa) than
pure alginate scaffolds (100/0: 1.6 ± 0.07 kPa) or pure chitosan
scaffolds (0/100: 4.0 ± 0.12 kPa). The differential elastic moduli of
the PEC formulations 60/40, 50/50 and 40/60 varied in a time-
dependent manner according to the plastic and/or viscous proper-
ties of these scaffolds. In contrast, pure alginate and pure chitosan
scaffolds maintained their initial properties. At the end of the first
compression, PEC scaffolds did not recover instantaneously their
initial physical shape. Consequently, 30 min later, when com-
pressed for the second time, the scaffolds, now more compact, pre-
sented a higher differential elastic modulus. Unlike the PEC
scaffolds, the pure alginate and pure chitosan scaffolds did recover
their initial mechanical properties/shape after compression.
Mechanical properties were significantly improved when alginate
and chitosan were associated.
3.2. In vitro evaluation of 3D PEC scaffolds
Human MSC compatibility was studied through the evaluation
of their metabolic activity, attachment and secretory properties.
Scaffold seeding was performed by the centrifugation procedure
described by Dar et al. [18].
3.2.1. Cell attachment on PEC scaffolds
MSC adhesion in the different alginate/chitosan formulations
was followed by immunostaining with antibodies against F-actin
(green), a cytoskeleton microfilament, and vinculin (red), a focal
adhesion protein, 3 days after seeding (Fig. 3).
MSCs cultivated in the 3D PEC scaffolds with a 60/40 and 50/50
ratio maintained their spherical shape, and their morphology re-
vealed a non-organized cytoskeleton. In addition, no focal adhesion
points between cells/scaffolds were found. For an alginate/chitosan
ratio of 40/60, we observed an organized cytoskeleton with many
focal adhesion points, as shown by the staining for F-actin and vin-
culin, respectively (Fig. 3A). A quantitative description of cell–scaf-
fold interaction was evaluated by measuring the mean cell area
3 days after seeding on 2D PEC films (Fig. 3B). Results revealed
the greatest cell surface when MSCs were cultured on pure chito-
san 2D films (1268 ± 300 lm2 for 0/100 polymer ratio) as com-
pared to pure alginate 2D films (317 ± 26 lm2 for 100/0 polymer
ratio). 2D PEC films presented an intermediate cell spreading (60/
40: 505.5 ± 150 lm2; 50/50: 366.5 ± 33; lm2 40/60:
569.4 ± 95 lm2).
3.2.2. Metabolic activity of MSCs cultured on 3D PEC scaffolds
We investigated whether the alginate/chitosan ratio could af-
fect cell retention/metabolic activity after seeding. To this end,
20 000 MSCs were seeded by centrifugation on each type of 3D
PEC scaffold and metabolic activity was measured after 3 and
14 days of culture by Alamar Blue assay. Fig. 4 shows the relative
fluorescence intensity of cells seeded on scaffolds. The results were
normalized to the fluorescence intensity measured for 20 000
MSCs (the initial metabolic activity at the moment of seeding).
Interestingly, 3 days after seeding, the relative fluorescent inten-
sity was statistically higher in pure chitosan scaffolds than in other
scaffold formulations (P < 0.001). Fourteen days after seeding, in all
scaffolds, the relative fluorescence intensity reached values close to
that observed in pure chitosan, suggesting that all the 3D PEC
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MSCs (20 000 cells, number of seeded cells) and is presented as 1 (dotted line) in the Fig. Results are fold metabolic activity of 20 000 MSCs. ⁄⁄P 6 0.01, ⁄⁄⁄P 6 0.001, based on
ANOVA analysis.
scaffolds stimulate cell proliferation and/or metabolic activity.
These results show that the 3D PEC scaffold composition can affect
cell retention and/or metabolic activity in these scaffolds.
3.2.3. Paracrine activity of seeded MSCs
Paracrine factors secreted by MSCs play a major role in the ben-
eficial effects of cell therapy. Therefore, the functionality of MSCs
was investigated by quantification of HGF, FGF-2 and of the angio-
genic factor VEGF released in the supernatant of MSCs cultured in
3D PEC scaffolds. Analyses were performed 24 h after cell seeding
and the results were compared to the secretion levels obtained in
classical 2D culture plates of MSCs.
As shown in Fig. 5, we found that secretion of HGF (Fig. 5A),
FGF-2 (Fig. 5B) and VEGF (Fig. 5C) by MSCs differed according to
the culture conditions and the alginate/chitosan ratios. HGF and
FGF-2 secretion in the extracellular medium was higher for algi-
nate/chitosan ratios of 50/50 and 40/60 as compared to classical
2D culture. In contrast, VEGF secretion at these alginate/chitosan
ratios was similar to that observed in MSC 2D culture. These results
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Fig. 5. Paracrine activity of seeded human MSCs. Quantification of HGF (A), FGF-2
(B) and VEGF (C) released in the supernatant by human MSCs cultured in 3D PEC
scaffolds. Quantification was performed 24 h after seeding. ⁄ denotes a significant
difference compared to classical 2D culture of human MSCs on tissue culture plate
(⁄⁄P 6 0.01, ⁄⁄⁄P 6 0.001, based on ANOVA analysis), and   denote a significant
difference compared with human MSCs cultured on 100/0 3D alginate scaffolds ( 
P 6 0.05,   P 6 0.01,    P 6 0.001, based on ANOVA analysis).
Table 1
Evaluation of 3D PEC scaffold biocompatibility. White blood cell differential count,
hematocrit levels, lymphocytes, monocytes and granulocytes blood concentrations of
implanted rats at the baseline, 7 and 33 days after surgical procedure.
Day Sham MI MI + Patch MI + patch + MSCs P-value
White blood cells (103 mmÿ3)
0 9.45 ± 1.4 8 ± 3 10.3 ± 1.8 9.8 ± 4.2
7 13.8 ± 2.8 10.3 ± 4.4 11.4 ± 3.6 10.8 ± 4.2 p > 0.05
33 6.2 ± 0.6 9.5 ± 0.2 7 ± 1.1 6.7 ± 1.2 p > 0.05
Hematocrit (%)
0 45.2 ± 1 42.6 ± 0.1 43.7 ± 2.7 42.3 ± 2.8
7 38.1 ± 1.5 37.3 ± 2.8 38.8 ± 1.6 40.3 ± 4.4 p > 0.05
33 44.6 ± 0.6 42.8 ± 1.5 40.4 ± 3.3 42.0 ± 3.6 p > 0.05
Lymphocytes (103 mmÿ3)
0 8.1 ± 0.6 7.0 ± 2.7 8.6 ± 1.4 8.4 ± 2.3
7 10.8 ± 2.3 8.3 ± 3.0 7.7 ± 1 7.5 ± 1.5 p > 0.05
33 7.3 ± 2.7 5.5 ± 0.8 5.5 ± 0.8 5.5 ± 1.1 p > 0.05
Monocytes (103 mmÿ3)
0 0.8 ± 0.14 0.47 ± 0.21 0.80 ± 0.26 0.78 ± 0.35
7 2.2 ± 0.49 1.13 ± 0.90 1.60 ± 1.00 1.44 ± 1.15 p > 0.05
33 0.83 ± 0.53 0.53 ± 0.06 0.63 ± 0.15 0.54 ± 0.15 p > 0.05
Granulocytes (103 mmÿ3)
0 0.7 ± 0.1 0.53 ± 0.21 0.98 ± 0.42 1.08 ± 0.51
7 1.50 ± 0.1 0.90 ± 0.60 2.18 ± 1.65 2.02 ± 2.13 p > 0.05
33 1 ± 0.53 0.70 ± 0.10 0.85 ± 0.25 0.66 ± 0.21 p > 0.05
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Fig. 6. Effect of 3D PEC scaffold implantation on cardiac function. Left ventricular
ejection fraction (A) and left ventricular end-diastolic volume (B), assessed by
echocardiography at the baseline (2 days before surgical procedure) and 4, 11, 25
and 32 days after surgical procedure. ⁄P 6 0.05, ⁄⁄⁄P 6 0.001 vs. MI, based on ANOVA
analysis.
show that association of alginate and chitosan, in particular at 50/
50 and 40/60 ratios, promotes, or at least maintains, the paracrine
activities of MSCs.
3.3. In vivo evaluation of 3D PEC scaffolds
In vitro experiments showed that alginate/chitosan ratios of 50/
50 and 40/60 were the most appropriate in term of microstructure,
mechanical resistance and stimulation of MSC paracrine activity. In
addition, an alginate/chitosan ratio of 40/60 appeared to promote
cell adhesion and cytoskeleton organization. Therefore, we se-
lected this formulation for the in vivo experiments.
3.3.1. Cardiac implantation of 3D PEC scaffolds
The in vivo effects of 3D PEC scaffolds with an alginate/chitosan
ratio 40/60 ratio were studied in a rat model of MI. MI was
achieved by a definitive ligature of the left anterior descending ar-
tery. 3D PEC scaffolds were then fixed to the myocardium by a sin-
gle suture onto the injured site. Rats were randomly distributed
into four groups: (1) sham-operated animals (SHAM, n = 4), sub-
jected to a thoracotomy and pericardectomy; (2) myocardial in-
farcted group (MI, n = 3), subjected to MI; (3) 3D PEC scaffold
implanted group (MI + 3D PEC, n = 4), subjected to MI and implan-
tation with an a cellular scaffold; and (4) group implanted with 3D
PEC scaffolds seeded with MSCs (MI + 3D PEC + MSCs, n = 6), sub-
jected to MI and implantation with a 3D PEC scaffolds seeded with
rat bone marrow MSCs.
The in vivo compatibility of the 3D PEC scaffolds (seeded or not)
was studied after implantation in a cardiac ischemic model.
Hematocrit was analyzed and white blood cells were numbered
at baseline and at 7 and 33 days after implantation in each differ-
ent group. No significant differences were observed for these
parameters between the control group, the MI group and the acel-
lular scaffold- or MSC-seeded 3D PEC scaffold-implanted groups
(Table 1).
3.3.2. Cardiac function
Cardiac function was determined by echocardiography at base-
line, 4, 11, 25 and 32 days after surgical procedure. The time
course summary of echocardiography data is shown in Fig. 6.
After MI (4 days after the beginning of the protocol), the ejection
fraction decreased significantly (Fig. 6A, P < 0.01). The ejection
fraction remained less than 50% for the group with MI and MI
with acellular 3D PEC scaffolds during the time course of the pro-
tocol: 32 days. In contrast, the ejection fraction of the group with
3D PEC scaffolds seeded with MSCs (MI + 3D PEC + MSCs) showed
an improvement compared to the control group (MI). Echocardi-
ography performed at 32 days post-treatment demonstrated an
improvement in LV function (P < 0.05). Statistically, the end-dia-
stolic volume remained the same during the time course of the
protocol (Fig. 6B).
3.3.3. Macroscopic and microscopic observations of explants
Post-mortem analyses after 33 days post-implantation revealed
that no adherences were observed in the environment of im-
planted 3D PEC scaffolds and in the thoracic wall. 3D PEC scaffolds
were found still attached to the left ventricle, covering the ische-
mic area (Fig. 7).
Red Sirius staining of rat hearts (MI group, Fig. 8B–D) showed
that rats with MI presented a decrease in the size of left ventricular
wall associated with an intense fibrotic response compared to con-
trols (Fig. 8A). This was confirmed by quantification of scar thick-
ness (Fig. 8E) and fibrosis (Fig. 8F) in each group. A weak
decrease in the fibrosis percentage was observed in rats implanted
with acellular 3D PEC scaffolds as compared to rats without
implanted scaffolds (Fig. 8F, P > 0.05). This tendency was more
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Fig. 7. Macroscopic view of explanted 3D PEC scaffolds 33 days post-implantation.
Scaffold covering the necrotic zone 33 days after the graft. Scale bar corresponds to
5 mm.
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based on ANOVA analysis.
important when scaffolds were seeded with MSCs (Fig. 8F,
P > 0.05).
Interestingly, we observed, in parallel to a tendency for a de-
crease in ventricular fibrosis, a significant increase in SMA staining
(Fig. 9), with a circular morphology typical of vascular walls. Quan-
tification of such SMA staining showed a significant increase in the
rat group implanted with acellular scaffolds as compared to rats
without implanted scaffolds (P < 0,001, MI group). The presence
of MSCs further increased SMA staining as compared to the acellu-
lar scaffold-implanted group (P < 0.001). These results suggest that
MSCs included in 3D PEC scaffolds promote myocardial
angiogenesis.
4. Discussion
The aim of this study was to evaluate the potential of MSCs/3D
PEC scaffolds for heart tissue engineering. With this in mind, algi-
nate was associated with chitosan, which appears particularly
interesting because of its strong mechanical properties and its abil-
ity to promote cell adhesion [29]. Opposite-charge PECs generated,
after freeze-drying, mixed alginate/chitosan 3D PEC scaffolds.
These scaffolds were designed with a patch shape for application
onto the myocardium ischemic area. This study reports for the first
time the use of chemically unmodified chitosan to improve algi-
nate properties and the design of 3D PEC scaffolds seeded with
MSCs for heart tissue engineering. The association of calcium-
cross-linked alginate with chitosan resulted in biomimetic and bio-
compatible scaffolds with adapted microstructure and mechanical
properties. In addition, alginate/chitosan scaffolds showed im-
proved in vitro and in vivo performance.
As reported previously by other teams, cardiac tissue is a non-
Hookean material with a differential elastic modulus close to
20 kPa [30–33]. All 3D PEC scaffolds displayed mechanical proper-
ties with viscoelastic and/or plastic behavior and a differential
elastic modulus (between 10 and 40 kPa) compatible with cardiac
tissue. Chitosan addition significantly improved the scaffolds’
mechanical resistance, which appeared 10–20 times higher than
that in pure alginate or pure chitosan scaffolds. Synergistic poly-
mer interaction led to an improvement in the mechanical behavior
of 3D PEC scaffolds [27].
After freeze-drying, PEC networks for all alginate/chitosan ra-
tios showed a highly porous interconnected homogeneous struc-
ture on surface and cross-sections. Pore dimensions of 50–
250 lm, on both surface and cross-sections, were compatible with
cell culture. Moreover, MSCs seeded on the surface of 3D PEC scaf-
folds could be disseminated through the scaffold body by centrifu-
gation. This method appears particularly convenient for 3D cell
seeding [18]. In this configuration, cells can be 3D cultured in con-
ditions mimicking the in vivo environment [34–37]. In contrast to
alginate, chitosan is well known to improve cell adhesion [29,38]
but little is known about the effects of the association of chitosan
and alginate on cell adhesion, survival and activities. Our results
show that 14 days after seeding, cell metabolic activity in all matri-
ces increased, suggesting that all the PEC scaffolds and combina-
tions of alginate and chitosan stimulate cell proliferation/
metabolic activity.
MSC functionality was analyzed 24 h after seeding by quantifi-
cation of cytokine released in the medium. These results clearly
show that polyelectrolyte alginate/chitosan scaffolds increased
the ability of MSCs to secrete HGF and FGF-2 as compared to MSC
2D cultures on tissue culture plates. The mechanisms responsible
for the changes in paracrine activity of MSCs in scaffolds are un-
clear. It is possible that interaction of MSCs with biomatrices may
activate plasmamembrane receptors and/or adhesion proteins reg-
ulating the secretory properties of MSCs. Spatial cell configuration,
cell density, and themechanical and chemical properties of 3D scaf-
folds may also affect paracrine activity [39–43]. Additional studies
will be necessary to confirm this hypothesis.
Our objective was to improve the microenvironment of grafted
cells in cardiac cell therapy. PEC formation between alginate and
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chitosan achieved this goal in terms of scaffold porosity and
mechanical properties. Moreover, these scaffolds appeared to have
bioactive effects on the cell adhesion and secretory properties.
The evaluation of 3D PEC scaffolds in an acute MI model demon-
strated the suitability of these scaffolds for cardiac cell therapy
using MSCs. Indeed, the use of MSC/3D PEC scaffolds significantly
improved cardiac function, decreased ventricular fibrosis and pro-
moted angiogenesis near the necrotic zone. Some studies previously
reported that implantation of acellular biomaterials improved car-
diac function. In these acellular strategies, the beneficial effects
were related to the mechanical stress exerted by the scaffold on
the left ventricle and its ability to overcome the loss of cardiac con-
tractility [44] and mimic extracellular matrix functions [45,46].
Moreover, such devices seemed to prevent ventricular dilatation
[47–50]. In our study, we also observed that acellular scaffolds pre-
vented ventricular dilatation after MI. However, ventricular func-
tion significantly improved only when implanted 3D PEC scaffolds
contained MSCs. The beneficial effects of implanted MSC/3D PEC
scaffolds were probably related to the secretion of paracrine factors
by MSCs. Indeed, in vitro studies showed that MSCs maintained
their ability to secrete HGF, FGF-2 and VEGF when cultured in 3D
PEC scaffolds. These growth factors are well known to be involved
in the positive effects of MSCs on tissue regeneration after ischemic
insult. Indeed, HGF reduces fibrotic response and promotes cytopro-
tection and angiogenesis [51–54]. FGF-2 and VEGF are also widely
reported to be involved in blood vessel formation [55–58]. Accord-
ing to these in vitro results, 3D PEC scaffolds seeded with MSCs im-
proved neovascularization around the necrotic zone after
implantation. Interestingly, we found that acellular scaffolds also
stimulated angiogenesis, albeit to a lesser extent. Therefore, the in-
crease in angiogenesis after scaffold deposition seems to be related
to both the properties of 3D PEC scaffolds and the paracrine activity
of MSCs. Other biomimetic materials, composed with fibrinogen,
are able to promote cell adhesion andplay an important role in angi-
ogenesis [59,60]. 3D PEC scaffolds synthesized with alginate and
chitosan have been previously proposed for cartilage and bone tis-
sue engineering [24, 61–64]. As compared to the experimental pro-
tocols used in our study, those described for cartilage and bone
tissue engineering included generation of hydrated PEC scaffolds
without a freeze-drying step, with 50/50 formulation and 4.8% (w/
w) of final polymer concentration. This protocol resulted in
mechanical properties similar to those of bone tissue (8.16 MPa).
Such properties significantly differ from those of heart tissue and
our 3D PECs. It has also been shown that 3D PEC scaffolds can sup-
port MSC culture for 14 days, and the biocompatibility of the con-
struct after implantation in rats has been demonstrated.
Our work reports for the first time the combination of alginate
and chitosan to generate highly porous scaffolds answering to
specifications required for both 3D culture and cardiac implanta-
tion. Our results on cardiac function and tissue cardiac morphology
demonstrate the efficacy of this bioengineering approach for cell
therapy of ischemic heart disease.
5. Conclusions
The present study describes the elaboration and the evaluation
of macroporous 3D PEC scaffolds designed to improve alginate
scaffold performance in cardiac stem cell therapy. Among the dif-
ferent compositions we tested, the 40/60 alginate/chitosan PEC
scaffolds presented a suitable porous microstructure, as well as
suitable mechanical and biological properties for in vitro MSC cul-
ture. Moreover, after evaluation in a rat model of acute MI, the
grafted MSCs enhanced the positive effect of the scaffolds and sig-
nificantly improved cardiac function. Our results show that these
40/60 3D PEC scaffolds have potential to serve as a useful tool
for cardiac tissue engineering.
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